Modulation of epidermal growth factor heterodimer activity
First Claim
Patent Images
1. A method for screening a plurality of compounds for an ability to bind to a heterodimer of EGFR and another ERBB family member, the method comprising:
- (a) contacting a first structure comprising an EGFR/ERBB heterodimer with a first solution, the first solution comprising the plurality of compounds, wherein the EGFR/ERBB heterodimer comprises an ERBB family member comprising the amino acid sequence set forth in SEQ ID NO;
6;
(b) removing any compounds bound to the first structure to produce a second solution;
(c) contacting a second structure comprising an EGFR homodimer with the second solution, wherein the first structure and the second structure are identical except that the second structure does not contain an ERBB family member other than EGFR; and
(d) recovering any unbound compounds to produce a third solution,whereby a compound that binds to a heterodimer of EGFR and another ERBB family member is identified.
2 Assignments
0 Petitions
Accused Products
Abstract
Provided is a method for screening a plurality of compounds for an ability to bind to a heterodimer of EGFR and another ERBB family member. Also provided are compounds that bind to heterodimers of EGFR and another ERBB family member, and methods of using the identified compounds to suppress the growth of a tumor associated with EGFR heterodimer activity in a subject.
9 Citations
12 Claims
-
1. A method for screening a plurality of compounds for an ability to bind to a heterodimer of EGFR and another ERBB family member, the method comprising:
-
(a) contacting a first structure comprising an EGFR/ERBB heterodimer with a first solution, the first solution comprising the plurality of compounds, wherein the EGFR/ERBB heterodimer comprises an ERBB family member comprising the amino acid sequence set forth in SEQ ID NO;
6;(b) removing any compounds bound to the first structure to produce a second solution; (c) contacting a second structure comprising an EGFR homodimer with the second solution, wherein the first structure and the second structure are identical except that the second structure does not contain an ERBB family member other than EGFR; and (d) recovering any unbound compounds to produce a third solution, whereby a compound that binds to a heterodimer of EGFR and another ERBB family member is identified. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
Specification